In our"Ask the Expert" series, leading CLL specialists answer audience questions. If you have a question for our experts, submit it now to email@example.com.
What Is the significance of the IGHV mutation status? Dr. Jeff Sharman explains.
Will using newer treatments as a frontline treatment decrease future efficacy of FCR if the patient becomes refractory? Dr. Jeff Sharman explains.
Dr. Nicole Lamanna answers a viewer’s question about approval of venetoclax for 11q deletion patients.
Dr. Philip Thompson of MD Anderson Cancer Center discusses safety and efficacy of combined BTK inhibitor therapies in current studies.
Have a question for the CLL experts on the latest research, treatment approaches or side effects? Or do you want to learn more about the basics of the disease? Patient Power is talking to the experts all year-round, and we want to ask the questions most important to you. Submit your brief question for the experts here. Please note that we will do our best to ask all appropriate questions, however, we cannot guarantee an answer. Be sure to sign up to receive email alerts so that we can inform you whenever new content is posted.